Renato Corporation Enters Into Negotiations Ending Due Diligence to Invest in Stem Cell Research and Treatment Company, Tissu

Renato Corporation (FRANKFURT: 4OZ) is in negotiations to invest in Tissu, a company that provides regenerative and rejuvenating treatments to patients. Tissu is the only Government-permitted company in the world authorized to provide Stem Cell Treatment under license and with legal authority. The United Kingdom-based company has emerged as the brand leader in stem cell treatments. This has been achieved by providing patients with the very best of regenerative and rejuvenating treatments that modern medicine and science has to offer. Partnerships with some of the most reputable universities, medical institutes and research facilities and the Government of Seychelles provides patients with cost effective stem cell treatment.

Renato Corporation will maintain its primary focus on non-invasive early detection diagnostic technologies and treatments. The company believes the investment into Tissu and Stem Cell Treatment will provide Renato with additional revenues that can be re-invested into affordable medical diagnostic technologies.

The terms of the joint venture agreement are currently under negotiation and will be made public in the near future.

Direct investments in unique partnerships such as Tissu and Pic-See Inc. will remain part of Renato Corporation's ongoing commitment to broadening the company's involvement in not only diagnostic technologies but in some of the most recent medical treatment applications available.

www.renatocorp.com

About Renato Corporation

At Renato Corporation it is the company's objective to provide diverse early detection diagnostic technologies utilizing its current experience, reputation and expertise within the international health care industry. Introducing and making available these non-invasive technologies through private health care firms and health and wellness centres in an affordable manner is our immediate focus.

The company's mission is to carefully select where these advanced diagnostic technologies will be placed to ensure unparalleled delivery of customer service and satisfaction in the field of non-invasive early detection disease diagnosis and management.

Innovative information technology platforms are enabling new models for more efficient, effective and safer healthcare delivery. It is inevitable, that the economic strain on today's health care systems worldwide will realize the ever increasing need for early detection diagnostic devices and services.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.